Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain.
To examine in vivo effectiveness of antisense oligonucleotides against tryptophan hydroxylase (TPH) mRNA, adult male swiss-NIH mice were implanted with in-dwelling cannula into the 4th ventricle and after recovery infused with either antisense oligonucleotide to TPH, scrambled control oligo or saline vehicle for four consecutive days. An additional group of animals bearing cannula were injected a single time i.p. with the TPH inhibitor para-chlorophenylalanine (PCPA; 300 mg/kg). All animals were sacrificed on the afternoon of the 4th day of treatment. TPH activity was measured by enzymatic assay and HPLC quantification of end-product synthesis. There was a significant decrease (> 50%) in TPH activity in both the PCPA-treated and antisense-oligo infused animals compared to either scrambled-oligo or saline-infused subjects (ANOVA; P < 0.05). There was no difference between saline and scrambled oligo-infusion. In a separate group of animals treated in the same way, behavioral tests were conducted on the afternoon of the 4th day. Two tests of anxiety, the hole-board apparatus and the elevated plus-maze, indicated some significant effects of PCPA treatment and/or antisense oligo-infusion but confounding effects due to alterations in locomotion could not be ruled out. However, tests on a rotorod apparatus indicated that antisense oligo-infused animals retained good balance and coordination in that their performance significantly improved on the second test, as did that of scrambled-oligo infused animals. In contrast, PCPA-treated animals did not improve, suggesting that locomotor performance had been impaired. These data support the notion that antisense oligo blockade may offer advantages over pharmacological manipulations of enzyme activity.
McCarthy
M M
MM
Department of Physiology, University of Maryland School of Medicine, Baltimore, USA.
Nielsen
D A
DA
Goldman
D
D
D000704:Analysis of Variance; D000818:Animals; D001007:Anxiety / Q000523:psychology; D001483:Base Sequence; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009043:Motor Activity / Q000187:drug effects; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000494:pharmacology*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000494:pharmacology; D014365:Tryptophan Hydroxylase / Q000037:antagonists & inhibitors* / Q000235:genetics; D010133:p-Chloroamphetamine / Q000009:adverse effects / Q000494:pharmacology
D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D012702:Serotonin Antagonists; D010133:p-Chloroamphetamine; D014365:Tryptophan Hydroxylase